Translational Development Acquisition (TDACW) Common Equity (2023 - 2026)

Translational Development Acquisition (TDACW) has reported Common Equity for 4 consecutive years, with -$7.7 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Common Equity fell 24.62% year-over-year to -$7.7 million; the trailing twelve-month figure through Jun 2026 stood at -$7.7 million (down 24.62% YoY), and the FY2025 full-year result was -$6.5 million, down 16.87% from the prior year.
• Common Equity declined to -$7.7 million in Q2 2026 per TDACW's latest filing, from -$6.8 million in the prior quarter.
• Across five years, Common Equity topped out at -$507658.0 in Q4 2023 and bottomed at -$7.7 million in Q2 2026.
• Historically, Common Equity has averaged -$5.1 million across 4 years, with a median of -$6.2 million in 2025.
• The sharpest annual moves came in 2025 and 2026: Common Equity slumped 1018.03% in 2025, then declined 14.77% in 2026.
• Over 4 years, Common Equity stood at -$507658.0 in 2023, then plunged by 1002.63% to -$5.6 million in 2024, then slipped by 16.87% to -$6.5 million in 2025, then declined by 17.46% to -$7.7 million in 2026.
• According to Business Quant data, Common Equity over the past three periods registered -$7.7 million, -$6.8 million, and -$6.5 million for Q2 2026, Q1 2026, and Q4 2025 respectively.